Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.51 |
| ▸ | FPR1 | P21462 | 2/20 | 0.43 |
| ▸ | FPR2 | P25090 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.42 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.42 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.42 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2069161 | 0.99 | EPHX2 (0.50) | EPHX2FPR1FPR2NPC1RAB9A | |
| SCHEMBL2068031 | 0.89 | MTOR (0.52) | EPHX2KCNH2 | |
| SCHEMBL18536615 | 0.89 | MTOR (0.52) | EPHX2KCNH2 | |
| Hydrochloric Acid SCHEMBL2067983 | 0.88 | MTOR (0.52) | EPHX2KCNH2 | |
| SCHEMBL13962125 | 0.85 | EPHX2 (0.49) | EPHX2FPR2NPC1RAB9A | |
| SCHEMBL18536590 | 0.85 | EPHX2 (0.49) | EPHX2FPR2NPC1RAB9A | |
| SCHEMBL2067558 | 0.85 | EPHX2 (0.49) | EPHX2FPR2NPC1RAB9A | |
| SCHEMBL9970015 | 0.85 | USP30 (0.43) | NPC1RAB9AKCNH2 | |
| Hydrochloric Acid SCHEMBL2068908 | 0.84 | EPHX2 (0.48) | EPHX2FPR2NPC1RAB9A | |
| Hydrochloric Acid SCHEMBL2068136 | 0.84 | USP30 (0.42) | NPC1RAB9AKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8431597-B2 | Benzimidazole derivatives | PFIZER INC. (US) | 2013-04-30 | — | — | US | disclosed |
| US-8431597-B2 | Benzimidazole derivatives | PFIZER INC. (US) | 2013-04-30 | — | — | US | disclosed |
| US-20120157495-A1 | BENZIMIDAZOLE DERIVATIVES | PFIZER INC. | 2012-06-21 | — | — | US | disclosed |
| US-20120157495-A1 | BENZIMIDAZOLE DERIVATIVES | PFIZER INC. | 2012-06-21 | — | — | US | disclosed |
| US-8148401-B2 | Benzimidazole derivatives | PFIZER INC. (US) | 2012-04-03 | — | — | US | disclosed |
| US-8148401-B2 | Benzimidazole derivatives | PFIZER INC. (US) | 2012-04-03 | — | — | US | disclosed |
| US-20090005416-A1 | BENZIMIDAZOLE DERIVATIVES | PFIZER INC. | 2009-01-01 | — | — | US | disclosed |
| US-20090005416-A1 | BENZIMIDAZOLE DERIVATIVES | PFIZER INC. | 2009-01-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090005416-A1 | BENZIMIDAZOLE DERIVATIVES | BOD1L1, H1-3, BRIX1 | EPHX2 4587/4885FPR1 3403/4885FPR2 4184/4885 |
| US-20120157495-A1 | BENZIMIDAZOLE DERIVATIVES | BOD1L1, H1-3, BRIX1 | EPHX2 4587/4885FPR1 3403/4885FPR2 4184/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.